Abstract:OBJECTIVE Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide.Recurrent or metastatic (R/M) HNSCC have rare treatment methods with poor prognosis.Recently,immunotherapy,especially immune checkpoint inhibitors,has make great breakthrough in solid tumors such as melanoma and lung cancer.This review was to summarize the current status and perspectives of immunotherapy in R/M HNSCC.METHODS Two hundred and twenty-two related papers and clinical trails were searched with "head and neck squamous cell carcinoma,immunotherapy,immune checkpoint inhibitors,adoptive cell transfer,tumor vaccine" as key words within PubMed or CNKI database retrieval system and ClinicalTrials.gov website from January 2001 to January 2017,and 38 were finally selected according to the inclusion criteria as follows:(1) R/M HNSCC；(2) current status and future perspective of immunotherapy;(3) immunotherapy related clinical trials.RESULTS Researches of immunotherapy in R/M HNSCC immunotherapy have developed wildly and deepened gradually,especially immune checkpoint inhibitors.Programmed cell death-1(PD-1) inhibitors (pembrolizumab and nivolumab) showed obvious effect,and were approved by food and drug administration (FDA) for the treatment of R/M HNSCC.Although there are no results of phase 3 clinical trials related to other immune checkpoint inhibitors,such as programmed death ligand-1 (PD-L1) inhibitors (durvalumab and avelumab) and Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors (ipilimumab and tremelimumab)published,a series of clinical trials are ongoing.The modes of adoptive cell transfer and tumor vaccine are explored.Besides,many aspects of immunotherapy in R/M HNSCC,such as screening patients according to biomarkers,improving efficacy with combination methods,monitoring and treatment of adverse events also catch our attentions.CONCLUSIONS Immunotherapy has a bright prospect in R/M HNSCC,but there are also many challenges.Future studies should focus on how to screen the most effective population,explore immune treatment modes and improve the efficacy of immunotherapy.

The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)

Immunotherapy for head and neck cancer: Recent advances and future directions

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Role of programmed death protein-1/programmed death ligands signaling pathway and the antibodies in the therapy of head and neck cancers

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

PD-1 Blockade Attenuates Immunosuppressive Myeloid Cells Due to Inhibition of CD47/SIRPα Axis in HPV Negative Head and Neck Squamous Cell Carcinoma

Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus

PD-1/PD-L1 Blockade in Cervical Cancer: Current Studies and Perspectives

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma

Immunotherapy for head and neck cancer: latest developments and clinical potential

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy

Immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: current status and future explorations